Roche (RHHBY) announced the approval of the CE Mark for the Ventana HER2 Rabbit Monoclonal Primary Antibody RxDx to identify metastatic breast cancer patients with low HER2 expression for whom Enhertu may be considered as a targeted treatment. The test, which is branded Pathway in the United States, received FDA approval in October 2022. Enhertu is a specifically engineered HER2-directed antibody drug conjugate being jointly developed and commercialised by Daiichi Sankyo and AstraZeneca (AZN).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Roche receives FDA approval for molecular test to screen blood donors for malaria
- Roche receives FDA approval for the first molecular test to screen for malaria in blood donors
- Rocheâs mixed myasthenia gravis data sending these stocks in opposite directions
- Tourmaline Bio might see weakness today after Roche MG data, says Truist
- Immunovant rallies after Chugai myasthenia gravis study failure
